Carnegie acted as joint book-runner in the initial public offering of Nordic Nanovector on Oslo Stock Exchange. The Company aspires to become a leading provider of Antibody-Radionuclide-Conjugate clinical solutions, to address major unmet medical needs and to advance cancer care through its innovative therapy programs and patented technologies. March 2015.
Healthcare
Initial public offering of Nordic Nanovector (NO) on Oslo Stock Exchange — NOK 575 million
March 2015